Can I Take Folate with Enclomiphene Citrate?

The Practical Answer

Folate is not listed as an interaction in the published enclomiphene trials, and the two do not have a known absorption conflict that requires spacing. However, the absence of a signal in small trials is not the same as a dedicated drug-supplement interaction study. The most accurate answer is that a clinically important interaction has not been demonstrated.

There is also no evidence that folic acid or methylfolate makes enclomiphene raise testosterone more reliably, prevents its adverse effects, or preserves fertility beyond the effects studied for enclomiphene alone. Tell the prescriber about the supplement and dose, especially if it is part of a fertility regimen with several ingredients.

Enclomiphene's US Approval and Access Status

Enclomiphene is the trans-isomer found within clomiphene citrate. It was studied as a separate product for men with secondary hypogonadism, but FDA materials describe a 2015 complete response rather than approval of the proposed application (FDA Pharmacy Compounding Advisory Committee briefing). That means there is no FDA-approved enclomiphene prescribing information establishing indications, standardized products, doses, or monitoring.

This is distinct from clomiphene citrate, an FDA-approved mixture of enclomiphene and zuclomiphene labeled for ovulatory dysfunction in selected women. A clomiphene label cannot be presented as an enclomiphene label for men. If a clinic offers enclomiphene, ask whether the dispensed product is compounded, which pharmacy made it, what concentration and excipients it contains, and how identity and potency are documented.

What the Human Trials Actually Showed

A small phase II study compared enclomiphene with testosterone gel in men previously treated with topical testosterone. Investigators measured testosterone, estradiol, LH, FSH, and sperm parameters; the study reported increased endogenous testosterone and sperm counts (PMID 23530575).

Two phase III trials in overweight men with secondary hypogonadism reported that enclomiphene raised testosterone while maintaining LH, FSH, and sperm counts compared with testosterone gel (PMID 26496621). These trials do not prove improved pregnancy or live-birth outcomes, do not establish long-term safety, and did not test folate as a co-therapy.

That boundary matters for fertility searchers. Preserving a laboratory sperm concentration is not the same as demonstrating that a folate-enclomiphene combination improves conception.

When Folate Is Useful

The NIH folate fact sheet lists an adult recommended dietary allowance of 400 mcg dietary folate equivalents for most adults. Folate is essential for DNA synthesis and one-carbon metabolism. Supplementation may be appropriate for inadequate intake, folate-deficiency megaloblastic anemia, or another clinician-directed indication.

Folate status is only one part of evaluating an elevated homocysteine level. Vitamin B12 status, kidney function, thyroid disease, diet, smoking, and medications can also matter. High-dose folic acid can correct the anemia of B12 deficiency without preventing neurologic injury, so numbness, balance problems, cognitive change, or unexplained macrocytosis should prompt evaluation rather than automatic folate escalation. The B12 with enclomiphene guide covers those distinctions.

What About MTHFR and Methylfolate?

Common MTHFR variants do not establish that a person taking enclomiphene needs methylfolate, and there is no enclomiphene trial stratified by MTHFR genotype. A supplement may still be appropriate for a separate nutritional or reproductive indication, but “methylation support” is not a substitute for diagnosing hypogonadism or infertility.

Men being evaluated for infertility need a history, examination, semen analysis, and targeted endocrine or genetic testing based on the clinical picture. A high-dose folate stack can add cost without answering whether the problem is secondary hypogonadism, a testicular condition, obstruction, medication effect, or a partner factor.

Monitoring Questions to Ask

Because enclomiphene lacks an approved label, there is no universal monitoring schedule. A responsible plan should still define:

• The diagnosis and symptoms being treated
• Two properly timed baseline testosterone measurements when evaluating hypogonadism
• Baseline LH and FSH to distinguish primary from secondary patterns
• Fertility goals and whether semen analysis is relevant
• Which symptoms or laboratory results will trigger a change
• The source and concentration of the product
• A stop date or reassessment point rather than open-ended automatic refills

Trial endpoints included testosterone, LH, FSH, estradiol, and sperm measures, but that does not mean every person needs every test at the same interval. The prescriber should tailor monitoring and promptly review visual symptoms, severe headache, mood change, breast symptoms, thromboembolic symptoms, or a marked estradiol rise. The zinc with enclomiphene guide applies the same evidence rule to another commonly marketed fertility supplement.